BHVN — Biohaven Pharmaceutical Holding Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousLarge CapMomentum Trap
- $10.31bn
- $10.88bn
- $462.51m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.98 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -65.64% | ||
| Return on Equity | n/a | ||
| Operating Margin | -70.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 63.63 | 462.51 | 1,044.25 | 1,331.64 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.
Directors
- Vlad Coric CHM (50)
- Matthew Buten CFO
- Kimberly Gentile SVP (55)
- Charles Conway CSO (59)
- William Jones OTH (56)
- Elyse Stock OTH (63)
- John Tilton OTH (53)
- Michael Heffernan LED (56)
- Kishen Mehta DRC
- Gregory Bailey IND
- John Childs IND (79)
- Julia Gregory IND (68)
- Robert Hugin IND (66)
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- September 25th, 2013
- Public Since
- May 4th, 2017
- No. of Shareholders
- 70
- No. of Employees
- 928
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 71,043,181
- Address
- 215 Church St, NEW HAVEN, 06510-1803
- Web
- http://biohavenpharma.com/
- Phone
- +1 2034040410
- Auditors
- Ernst & Young LLP
Upcoming Events for BHVN
Q3 2022 Biohaven Pharmaceutical Holding Company Ltd Earnings Release
Similar to BHVN
ADC Therapeutics SA
New York Stock Exchange
Ambrx Biopharma
New York Stock Exchange
Annovis Bio
New York Stock Exchange
Arcus Biosciences
New York Stock Exchange
Charles River Laboratories International
New York Stock Exchange
FAQ
What is the Biohaven Pharmaceutical Holding share price?
As of Today at 13:03 UTC, shares in Biohaven Pharmaceutical Holding are trading at $145.14. This share price information is delayed by 15 minutes.
How has the Biohaven Pharmaceutical Holding share price performed this year?
Shares in Biohaven Pharmaceutical Holding last closed at $145.14 and the price had moved by +53.96% over the past 365 days. In terms of relative price strength the Biohaven Pharmaceutical Holding share price has outperformed the S&P500 Index by +77% over the past year.
What are the analyst and broker recommendations for Biohaven Pharmaceutical Holding?
The overall consensus recommendation for Biohaven Pharmaceutical Holding is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Biohaven Pharmaceutical Holding dividend yield?
Biohaven Pharmaceutical Holding does not currently pay a dividend.
Does Biohaven Pharmaceutical Holding pay a dividend?
Biohaven Pharmaceutical Holding does not currently pay a dividend.
When does Biohaven Pharmaceutical Holding next pay dividends?
Biohaven Pharmaceutical Holding does not currently pay a dividend.
How do I buy Biohaven Pharmaceutical Holding shares?
To buy shares in Biohaven Pharmaceutical Holding you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biohaven Pharmaceutical Holding?
As of the previous close price of $145.14, shares in Biohaven Pharmaceutical Holding had a market capitalisation of $10.31bn.
Where are Biohaven Pharmaceutical Holding shares listed?
Here are the trading details for Biohaven Pharmaceutical Holding:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: BHVN
What kind of share is Biohaven Pharmaceutical Holding?
Based on an overall assessment of its quality, value and momentum Biohaven Pharmaceutical Holding is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biohaven Pharmaceutical Holding share price forecast for 2022?
The analyst consensus target price for shares in Biohaven Pharmaceutical Holding is $153.56. That is 5.8% above the last closing price of $145.14.
Analysts covering Biohaven Pharmaceutical Holding currently have a consensus Earnings Per Share (EPS) forecast of -$11.31 for the next financial year.
What is the trend in the Biohaven Pharmaceutical Holding share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biohaven Pharmaceutical Holding. Over the past six months, its share price has outperformed the S&P500 Index by +49.46%.
As of the last closing price of $145.14, shares in Biohaven Pharmaceutical Holding were trading +14.64% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biohaven Pharmaceutical Holding PE Ratio?
The Biohaven Pharmaceutical Holding PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $145.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biohaven Pharmaceutical Holding?
Biohaven Pharmaceutical Holding's management team is headed by:
- Vlad Coric - CHM
- Matthew Buten - CFO
- Kimberly Gentile - SVP
- Charles Conway - CSO
- William Jones - OTH
- Elyse Stock - OTH
- John Tilton - OTH
- Michael Heffernan - LED
- Kishen Mehta - DRC
- Gregory Bailey - IND
- John Childs - IND
- Julia Gregory - IND
- Robert Hugin - IND